2004
DOI: 10.1016/s0140-6736(04)16506-9
|View full text |Cite
|
Sign up to set email alerts
|

Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets

Abstract: SARS coronavirus continues to cause sporadic cases of severe acute respiratory syndrome (SARS) in China. No active or passive immunoprophylaxis for disease induced by SARS coronavirus is available. We investigated prophylaxis of SARS coronavirus infection with a neutralising human monoclonal antibody in ferrets, which can be readily infected with the virus. Prophylactic administration of the monoclonal antibody at 10 mg/kg reduced replication of SARS coronavirus in the lungs of infected ferrets by 3.3 logs (95… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

4
237
0
3

Year Published

2004
2004
2015
2015

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 254 publications
(244 citation statements)
references
References 5 publications
4
237
0
3
Order By: Relevance
“…The WKV+alum vaccine induced 15-fold higher serum neutralizing antibody titres than the other vaccines, but this vaccine did not provide universally better protection. While human antibodies to S protein have shown some protective effect against SARS in ferrets (ter Meulen et al, 2004), our results show that high systemic neutralizing (Table 3). Lung samples were fixed for histology and stained with haematoxylin and eosin or PAS.…”
Section: Discussionmentioning
confidence: 55%
See 2 more Smart Citations
“…The WKV+alum vaccine induced 15-fold higher serum neutralizing antibody titres than the other vaccines, but this vaccine did not provide universally better protection. While human antibodies to S protein have shown some protective effect against SARS in ferrets (ter Meulen et al, 2004), our results show that high systemic neutralizing (Table 3). Lung samples were fixed for histology and stained with haematoxylin and eosin or PAS.…”
Section: Discussionmentioning
confidence: 55%
“…Our ferret SARS-CoV challenge resulted in ferrets with clinical signs of infection (elevated temperature, nasal discharge and sneezing), in contrast to other reports using the same virus titre (Czub et al, 2005;ter Meulen et al, 2004;Weingartl et al, 2004). Our lab passed the Tor2 virus only once (a total of three passages) prior to challenge to avoid the accumulation of interfering particles or mutations due to tissue culture adaptation.…”
Section: Discussionmentioning
confidence: 97%
See 1 more Smart Citation
“…The humanized mAb palivizumab that is used clinically for prophylaxis against respiratory syncytial virus infection is given at a dose of 15 mg/kg (41), which translates into a dose of ϳ375-450 g of mAb to a 25-30 g mouse. Similarly, a fully human Ab to the severe acute respiratory distress syndrome coronavirus was used at a dose of 10 mg/kg to protect ferrets against infection (42). Thus, our use of 50 -150 g delivered topically to the lung of a 30 g mouse is within the range of mAb doses used in either human clinical medicine or to evaluate human mAbs in animal models of infection.…”
Section: Discussionmentioning
confidence: 99%
“…E, Equal amounts of the gradient fractions (nos. [3][4][5][6][7][8][9][10][11][12][13][14][15][16] were examined by Western blot analyses. m8, m8-infected RK13 cell lysate; ppt, m8rVV-NMES-infected RK13cell lysate; PC, RK13 cell lysates infected with mOrVV-NHis, mOrVV-MHis, mOrVV-EHis, or mOrVV-SHis.…”
Section: Generation Of Recombinant Vv That Expresses the Structural Pmentioning
confidence: 99%